22P Characterizing the cancer spectrum of germline SMARCA4 variants to estimate penetrance
Conclusions: Pembrolizumab either alone or in combination with chemotherapy conferred a benefit to 7 out of 10 patients with SCC arising from mature teratoma.Evaluation in a larger cohort and comparison of responders vs. non-responders is warranted to help future patient selection for this active treatment.
Authors
- Sue E. Crawford (ORCID: https://orcid.org/0000-0001-8113-3806)
- Rebecca Sisson
- Linda T. Brubaker (ORCID: https://orcid.org/0000-0002-8598-2589)
- X. Zhang (ORCID: https://orcid.org/0000-0001-5513-9657)
- Joseph G. Pressey (ORCID: https://orcid.org/0000-0003-1816-3281)
- Michaël Chandler (ORCID: https://orcid.org/0000-0002-0292-6662)
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- Center for Cancer and Blood Disorders (US)
- University of Colorado Cancer Center (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104331
- Primary Topic
- Chromatin Remodeling and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00